ABVX · Abivax SA

78.95

EUR

-3.00 (-3.661%)

16/10/2026 12:00:00 AM

Price change (7D)

Unlock stock Insights

Create a free account to unlock price targets, recommendations, and commentary.

Overview

Market Cap

Euro7.17B

0.00

EV/EBITDA

N/A

DIV Yield

0%

Payout Ratio

0%

MQV Rating

5Very Weak

As at 16/10/2026 12:00:00 AM

Price Chart

Description

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

All-Companies
All-Consensus
EMA 125 Breakdown
Engulfing Bearish (Realtime)
HALO 100
HALO 200
HALO 50
HALO All
HALO Earnings Momentum
HALO Momentum

Key Fundamentals

EPS 3 yr Growth

51.90%

EBITDA Margin

N/A

Operating Cashflow

-€162m

Free Cash Flow Return

-56.00%

ROIC

-116.10%

Interest Coverage

-8.80

Quick Ratio

8.70

Performance

52 weeks range

Low 60.45 - 139

Trade Value (12mth)

US$5,628,188.00

1 week

6.29%

1 month

-12.54%

YTD

-28.74%

1 year

7.69%

All time high

139.00

Additional Data

Shares Outstanding (Fully Diluted)

80m

HALO Sector

Healthcare

Next Company Report Date

29-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

EUR

Short Sell (% of issue)

0.00

Consensus

Unlock full consensus

Consensus score

/10

Recommendation

Buy

Target price

Deviation

Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Momentum

Price

Very Weak

Earnings

Very Strong

Growth

Earnings

Strong

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Neutral

Valuation

Unlock full dataset

Value

Consensus

Yield

News & Announcements

No announcements available.

Key Stakeholders

Name	Title
Invus Financial Advisors LLC	Private Company
Sofinnova Partners SAS	Private Company
Truffle Capital SAS	Private Company
Marc M. P. de Garidel	Individual
Didier Blondel	Individual